Amundi’s Tvardi Therapeutics TVRD Stock Holding History

Amundi’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-171	Closed	-$28.9K	–	2145
2023 Q1	$28.9K	Buy	+171	New	+$57.3K	﹤0.01%	1940

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amundi's TVRD Position: Q2 2023 in Review

Amundi sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 171 shares — an estimated $28.9K sold.

Amundi first reported a position in TVRD in Q1 2023 and held it in 1 quarter. The position peaked at $28.9K in Q1 2023. 136 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

Amundi reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
Amundi sold 171 Tvardi Therapeutics shares in Q2 2023, an estimated $28.9K.
Amundi first reported a position in Tvardi Therapeutics in Q1 2023 and held it in 1 quarter.
Amundi's Tvardi Therapeutics position peaked at $28.9K in Q1 2023.
136 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on Amundi's 13F filing for Q2 2023, filed 14 Aug 2023.